Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVisser, Otto-
dc.contributor.authorArdanaz, Eva-
dc.contributor.authorBotta, Laura-
dc.contributor.authorSant, Milena-
dc.contributor.authorTavilla, Andrea-
dc.contributor.authorMinicozzi, Pamela-
dc.contributor.authorCalleja, Neville-
dc.identifier.citationVisser, O., Ardanaz, E., Botta, L., Sant, M., Tavilla, A., Minicozzi, P. & Calleja, N. (2015). Survival of adults with primary malignant brain tumours in Europe ; results of the EUROCARE-5 study. European Journal of Cancer, 51(15), 2231-2241.en_GB
dc.description.abstractBackground: Primary malignant brain tumours are rare but represent a serious health burden due to their poor survival. This manuscript describes the survival of malignant brain tumours in adults diagnosed 2000–2007 in Europe. Methods: For this study we analysed patients archived in 86 European population-based cancer registries, followed up to 31st December 2008. Only primary malignant neuroepithelial brain tumours (with pathological confirmation) and primary malignant unspecified brain tumours without pathological confirmation were included. We estimated 1-year and 5-year relative survival (RS) weighted by age group and country. We also estimated country-specific and age-specific survival, together with survival differences between time periods (for 1999–2001, 2002–2004 and 2005–2007). Results: Glioblastoma represents 49% of all brain tumours, followed by other/unspecified astrocytoma (18%), oligodendroglioma/oligoastrocytoma (9%), ependymoma (1.5%) and embryonal tumours (1%). Five-year RS was 20% for all tumours combined, but ranged from 58% for ependymoma to only 6% for glioblastoma and sharply decreased with increasing age. Differences between countries were relatively small, but generally RS in Ireland/United Kingdom (UK) and Eastern Europe was below the average. An increase in 1-year RS (up to 10–12%) was noted over time, being largest in Central and Northern Europe in patients between 45 and 74 years of age. Conclusions: Despite an increase in 1-year RS in most European regions, the survival of primary malignant brain tumours is still poor. Disparities between countries were evident, being even larger at the end of the study period than at the beginning, suggesting differences in availability of the latest treatment modalities.en_GB
dc.publisherElsevier Ltd.en_GB
dc.subjectBrain -- Tumorsen_GB
dc.subjectHealth surveysen_GB
dc.subjectTumors -- Patients -- Long-term careen_GB
dc.titleSurvival of adults with primary malignant brain tumours in Europe ; results of the EUROCARE-5 studyen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.publication.titleEuropean Journal of Canceren_GB
Appears in Collections:Scholarly Works - FacM&SPH

Files in This Item:
File Description SizeFormat 
  Restricted Access
2.08 MBAdobe PDFView/Open Request a copy

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.